Lilly Ventures
70
27M
37
3.04
13
0.47
25
- Areas of investment
Summary
The leading representative office of defined VC is situated in the Indianapolis. The fund was located in North America if to be more exact in United States. Lilly Ventures appeared to be a CVC structure as part of the corporation.
This organization was formed by Ron Laufer. We also calculated 2 valuable employees in our database.
Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 4 of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Receptos, Viracta Therapeutics, Serenex.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Lilly Ventures, startups are often financed by Polaris Partners, SV Health Investors, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are SR One, Polaris Partners, Atlas Venture. In the next rounds fund is usually obtained by Novartis Venture Fund, Venrock, SR One.
The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 8 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. The high activity for fund was in 2009. The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Lilly Ventures works on 2 percentage points more the average amount of lead investments.
Investments analytics
Analytics
- Total investments
- 70
- Lead investments
- 13
- Exits
- 25
- Rounds per year
- 3.04
- Follow on index
- 0.47
- Investments by industry
- Biotechnology (58)
- Health Care (39)
- Therapeutics (28)
- Medical (22)
- Pharmaceutical (19) Show 22 more
- Investments by region
-
- United States (62)
- Israel (2)
- Australia (2)
- United Kingdom (1)
- Peak activity year
- 2009
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Avg. valuation at time of investment
- 38M
- Group Appearance index
- 0.97
- Avg. company exit year
- 9
- Avg. multiplicator
- 1.97
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Lysosomal Therapeutics | 03 Feb 2015 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 20M | United States, Massachusetts, Cambridge |
| ONtheGO Platforms | 01 Jan 2014 | Software, Mobile, Augmented Reality, Internet of Things, Wearables, Human Computer Interaction, Google Glass | Seed | 713K | United States, Oregon, Portland |
| Serenex | 06 Oct 2005 | Biotechnology, Health Care, Medical | Late Stage Venture | 30M | United States, North Carolina, Durham |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.